Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies reported third-quarter 2021 revenues of $2.111 billion, down 1% from $2.138 billion year-over-year. GAAP net income surged to $188 million, compared to $71 million in Q3 2020. The company plans to launch IPOs for Solta Medical in December 2021 or January 2022, followed by Bausch + Lomb about 30 days later. Bausch Health reaffirmed its full-year 2021 guidance with revenue expectations of $8.40 – $8.60 billion and Adjusted EBITDA between $3.35 – $3.50 billion.
Bausch Health Companies (NYSE/TSX: BHC) will present seven scientific posters and data from its ARMOR surveillance study at the American Academy of Optometry and American Academy of Ophthalmology meetings held in November 2021. Key presentations include analyses on the newly FDA-approved XIPERE™ for macular edema and the Bausch + Lomb INFUSE® Multifocal contact lenses. The company's commitment to educating eye care professionals through promotional events highlights its dedication to addressing patient needs.
Bausch Health has launched the Biotrue® Eye Care Recycling program, the first of its kind in the United States, allowing consumers to recycle eye drop single dose units, lens cases, and Biotrue® multi-dose bottles. This initiative, in collaboration with TerraCycle, aims to reduce environmental waste from these products. Participants can sign up for the program, collect eligible items, and mail them to TerraCycle for proper recycling. The program supports Bausch's ongoing commitment to sustainability in eye care packaging.
Bausch Health and its subsidiary Salix Pharmaceuticals released the Liver Health Annual Trends Report, highlighting critical gaps in chronic liver disease (CLD) care in the U.S. The report surveyed 100 healthcare providers, revealing that 38% are unaware of CLD management guidelines. An alarming 51% do not follow current American Association for the Study of Liver Diseases (AASLD) guidelines. CLD affects approximately 4.5 million Americans, with increasing cases of nonalcoholic fatty liver disease noted. The report emphasizes the urgent need for improved education and adherence to treatment standards.
Bausch Health Companies Inc. (BHC) announced the presentation of seven research findings related to its products XIFAXAN®, TRULANCE®, and RELISTOR® at the American College of Gastroenterology 2021 Annual Scientific Meeting in Las Vegas, from October 22-27, 2021. The new clinical data aims to improve patient care for gastrointestinal disorders. Salix Pharmaceuticals, a subsidiary, leads this initiative, reflecting its commitment to advancing gastrointestinal health.
XIPERE™, approved by the FDA, is the first medication for suprachoroidal injection in the U.S., targeting macular edema associated with uveitis. Developed by Bausch Health (BHC) and Clearside Biomedical (CLSD), it facilitates targeted delivery to the retina, potentially mitigating vision loss. Clinical trials indicate that 47% of patients showed significant visual acuity improvement compared to 16% in the control group. The product will be available in Q1 2022, offering a new therapeutic option in the eye health market.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Tom Vadaketh as Chief Financial Officer (CFO) of Bausch Pharma, effective January 3, 2022. Sam Eldessouky will transition to CFO of Bausch + Lomb following its IPO completion. Vadaketh brings over 30 years of financial experience from various roles, including CFO positions at reputable firms. This leadership change aims to strengthen Bausch Pharma's financial management as they prepare for the IPO of their eye health business. The company emphasizes its commitment to advancing global health through innovative products.
Bausch Health Companies (NYSE/TSX: BHC) announced the presentation of eight posters at the Fall Clinical Dermatology Conference from Oct. 21-24, 2021. These posters will showcase analyses of the efficacy and safety of ARAZLO® (tazarotene) Lotion, DUOBRII® (halobetasol propionate and tazarotene) Lotion, and SILIQ® (brodalumab) injection. The presentations include key findings on long-term outcomes, quality of life improvements, and treatment recommendations for onychomycosis. Two educational events focusing on ARAZLO and DUOBRII will also be held during the conference.
Bausch + Lomb announced positive outcomes from the one-year evaluation of its LuxSmart™ lens, designed for continuous vision from distance to intermediate. Since its 2020 European launch, 5,000 cataract patients have been treated with the lens, adopted by 200 surgeons across 18 countries. Evaluation results indicate excellent vision performance with minimal dysphotopsia. The lens is preloaded and suitable for patients with co-morbidities, with up to 30% of patients gaining near vision.
There is a growing global market for presbyopia solutions, with an expected 1.8 billion people affected by 2050.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its third-quarter 2021 financial results on November 2, 2021, at 8:00 a.m. ET. The event will include a conference call for discussion on the results and a business update, accessible via the company's Investor Relations site. The company specializes in pharmaceutical, medical devices, and over-the-counter products focusing on eye health, gastroenterology, and dermatology.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
